This review article discusses the current status and research directions in acute myeloid leukemia (AML). Since 2017, twelve agents have been approved for AML treatment, including BCL2 inhibitors, FLT3 inhibitors, IDH inhibitors, and hypomethylating agents. These agents have been incorporated into effective regimens, improving outcomes for AML patients. The article highlights the importance of personalized treatment based on molecular and cytogenetic findings, as well as the need for targeted therapies in different AML subsets. It also discusses the role of measurable residual disease (MRD) in predicting outcomes and the importance of supportive care in AML treatment. The review emphasizes the need for further research and the development of new therapeutic strategies to improve survival rates and quality of life for AML patients. The article also discusses the challenges of treating older and unfit patients, and the potential benefits of lower-intensity therapies in these cases. Overall, the review highlights the progress made in AML treatment and the need for continued research to improve outcomes for patients with this disease.This review article discusses the current status and research directions in acute myeloid leukemia (AML). Since 2017, twelve agents have been approved for AML treatment, including BCL2 inhibitors, FLT3 inhibitors, IDH inhibitors, and hypomethylating agents. These agents have been incorporated into effective regimens, improving outcomes for AML patients. The article highlights the importance of personalized treatment based on molecular and cytogenetic findings, as well as the need for targeted therapies in different AML subsets. It also discusses the role of measurable residual disease (MRD) in predicting outcomes and the importance of supportive care in AML treatment. The review emphasizes the need for further research and the development of new therapeutic strategies to improve survival rates and quality of life for AML patients. The article also discusses the challenges of treating older and unfit patients, and the potential benefits of lower-intensity therapies in these cases. Overall, the review highlights the progress made in AML treatment and the need for continued research to improve outcomes for patients with this disease.